Familial hypertrophic cardiomyopathy (FHCM) is a genetic disorder characterized by thickening of the heart muscle, which can lead to structural and functional abnormalities of the heart. The disorder most often affects the left ventricle, but can affect other areas of the heart. Thickening of the heart muscle can cause outflow tract obstruction, impaired diastolic filling, and an increased risk of sudden cardiac death. FHCM often presents at a younger age and can have a wide range of clinical manifestations, making diagnosis and treatment difficult.
History of the disease and interesting historical facts
Familial hypertrophic cardiomyopathy was first described in the medical literature in the early 20th century. In 1958, researchers including Professor Henry H. Kaufman made a significant contribution to the study of the disease by coining the term “hypertrophic cardiomyopathy”. Notably, the 1980s saw a breakthrough in understanding the genetic basis of FHCM when scientists discovered mutations in genes encoding proteins of the heart muscle. Research in the 2000s demonstrated that FHCM is one of the most common genetic cardiovascular diseases that can be passed on from generation to generation, increasing interest in genetic testing and screening programs.
Epidemiology
According to various studies, the prevalence of familial hypertrophic cardiomyopathy ranges from 1:500 to 1:2000 in the population. This disease can be detected in both men and women, but in men, the disease is more often progressive with more pronounced symptoms. Statistics also confirm that about 50% patients with HFCM have a family history of the disease, indicating its hereditary nature. Warming studies show that having a first-degree relative diagnosed with HFCM increases the likelihood of developing the disease in subsequent family members. Thus, this emphasizes the need for genetic counseling to identify individuals at increased risk.
Genetic predisposition to this disease
Familial hypertrophic cardiomyopathy can be caused by mutations in more than 15 genes, mostly encoding sarcomeric proteins. The most common genes associated with FHCM include MYH7 (beta-mylase gene), MYBPC3 (cardiomyosin-binding protein gene), and TNNT2 (troponin gene). Mutations in these genes lead to abnormal structure and function of the heart muscle, which in turn provokes the development of hypertrophy. It is important to note that although most cases of FHCM are inherited in an autosomal dominant manner, precautions and diagnoses should also be taken into account when evaluating less common forms of inheritance and potential somatic changes.
Risk factors for the development of this disease
Risk factors that contribute to the development of familial hypertrophic cardiomyopathy can be divided into several groups:
- Genetic predisposition: having a patient in the family is the main risk factor.
- Physical factors: intense physical activity, especially in athletes, can trigger the manifestation of latent forms of the disease.
- Chemical factors: exposure to toxins and certain medications can worsen the course of the disease.
- Other factors: age, gender and comorbidities such as hypertension.
All these factors should be taken into account when assessing the likelihood of developing GMH, especially in individuals with a predisposition to hereditary diseases.
Diagnosis of this disease
Diagnosis of familial hypertrophic cardiomyopathy involves multiple steps and methods:
- Main symptoms: the disease often manifests itself as shortness of breath, heart rhythm disturbances, and chest pain.
- Laboratory tests: Cardiac markers such as troponins may be useful in assessing heart muscle damage.
- Radiological examinations: Echocardiography is the main imaging method for determining thickening of the heart walls and assessing its function.
- Other diagnostic tests: Magnetic resonance imaging can help in more detailed assessment of structural changes in the heart.
- Differential diagnosis: it is important to exclude other causes of myocardial hypertrophy, such as arterial hypertension or cardiomyopathy of other origins.
This multifaceted approach to diagnostics allows the doctor to get a complete picture of the patient's condition and confirm the diagnosis.
Treatment
Treatment of familial hypertrophic cardiomyopathy may include several methods aimed at correcting the patient's condition:
- General treatment: physical activity control and lifestyle changes to reduce symptoms of the disease.
- Pharmacological treatment: use of beta-blockers (propranolol, atenolol) and calcium antagonists (dihydropyridines) to reduce heart rate and reduce ischemic manifestations.
- Surgical treatment: In cases of severe obstruction, myectomy (removal of part of the thickened muscle) may be vital. In some cases, a pacemaker may need to be installed.
- Other treatments: Genetic counseling for relatives and family group screening are important steps.
An integrated approach with the inclusion of all these methods ensures optimal treatment and improves the quality of life of patients.
List of medications used to treat this disease
Among the drugs used to treat familial hypertrophic cardiomyopathy, the following can be distinguished:
- propranolol
- Atenolol
- Diltiazem
- Verapamil
- Aspirin
Each of the presented drugs should be prescribed taking into account the individual characteristics of the patient and the course of the disease.
Disease monitoring
Monitoring the condition of a patient with familial hypertrophic cardiomyopathy includes regular observation and assessment of:
- Control stages: regular visits to a cardiologist, periodic echocardiographic studies to assess the progression of myocardial thickening.
- Prognosis: With proper treatment and monitoring, many patients can live long, full lives. However, there is a significant risk of sudden cardiac death.
- Complications: heart rhythm disturbances, heart failure, thrombosis.
Effective monitoring allows for timely detection of complications and adjustment of treatment.
Age-related features of the disease
Familial hypertrophic cardiomyopathy can manifest itself in different age groups with varying degrees of severity:
- Children and adolescents: May present with earlier symptoms and a more severe course, often causing athletic limitations.
- Young people: Such patients may experience significant physical stress, which requires constant monitoring.
- Adults: Symptoms may stabilize, but regular monitoring and appropriate treatment are important.
- Elderly: This group has comorbidities that may complicate the course of SGCM.
Thus, age is critical in choosing a treatment scenario and potential complications of the disease.
Questions and Answers
- What is familial hypertrophic cardiomyopathy? It is a genetically determined disease that leads to thickening of the heart muscle and disruption of its function.
- What are the main symptoms of the disease? Shortness of breath, chest pain, uneven heart rhythm, and fatigue may be signs of this cardiomyopathy.
- How is GCMS diagnosed? The diagnosis is made on the basis of clinical presentation, echocardiographic studies and laboratory tests.
- How is this disease treated? Treatment includes drug therapy, lifestyle changes, and, in some cases, surgical correction.
- What are the prospects and prognosis for SGCM? With proper treatment, many patients can lead active lives, but regular monitoring is important.
Advice from Dr. Oleg Korzhikov
According to Dr. Oleg Korzhikov, an important aspect for patients with familial hypertrophic cardiomyopathy is a suitable lifestyle. He recommends:
- Avoid excessive physical activity and stress, which may worsen symptoms.
- Get regular check-ups and stay in touch with your doctor.
- Pay attention to the appearance of new symptoms and immediately report them to your doctor.
- Follow a diet and monitor your blood pressure.
These recommendations will help patients lead full lives despite having the disease.
